Open an account

Purple Biotech

PPBT · TEL

$1.08+$0.03 (+2.86%)TodayMarket closed ·
Prev close $1.05

PPBT analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 2 analysts

Average $0.00 (−100.0% downside)

Low
$0.00
Now
$1.08
High
$0.00

Upgrades and downgrades

The latest rating actions, newest first

PPBT analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Aug 7, 2026MaintainsBuy
HC Wainwright & Co.Mar 13, 2026MaintainsBuy

The case for and against

Updated Mar 8, 2025

Bull case

Purple Biotech Ltd is demonstrating significant progress in its clinical trials, particularly with its oncology pipeline's CM24, which has showcased an objective response rate (ORR) of 25%, substantially higher than the 6.7% seen in control groups. The company's results indicate a 25% reduction in the risk of death among the overall patient population, alongside a notable 2.1-month improvement in median overall survival (OS), indicating strong efficacy in treatment. Additional biomarker analyses from the Phase 2 CM24 trial further highlight positive outcomes, revealing substantial risk reductions in mortality and supporting the potential synergies between CM24 and existing therapies, which collectively contribute to a favorable outlook for Purple Biotech's stock.

Bear case

Purple Biotech Ltd faces significant risks that contribute to a negative outlook on its stock, including potential safety concerns in its clinical programs, lower-than-expected efficacy, and heightened competition from existing and emerging treatments. The company anticipates a need for approximately $60 million in additional financing by 2037, while its cash runway extends only into the second half of 2025, raising liquidity concerns. Furthermore, the risk of de-listing if shares fall below $1, along with issues related to regulatory decisions and intellectual property protection, compound potential challenges for the company's future growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.